TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of positive, indeterminate, negative tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supplemental analgesics ingested
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical Status at Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of urinary incontinence symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Infiltration of Immune Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fructose conversion into lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dietary intake of servings of fruit and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Seizure onset zone contacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Number of Participants with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived Thirst
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FEV1 / FVC Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced mid-expiratory flow (FEF25-75%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Beck Depression Inventory - II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of cigarettes or other toxic substances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cMax of docetaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal infrarenal aortic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Blood pressure measurements for PAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of the diameter of the individual lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of the size of the individual lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Visual changes of the wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: complete regression of respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete blood counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Comprehensive metabolic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Coagulation studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: work related musculoskeletal disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: muscular problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: nerve affection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in bioburden on surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUClast of Gemigliptin and Dapagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Gemigliptin and Dapagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery of Tobacco Treatment Services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Objective Clinical Response (CR/PR/SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Freedom from Ventricular Fibrillation/Tachycardia Recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of wounds completely healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects with Dose-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Distribution volume of radioligands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time stability of radioligands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drugs use reported by drivers
Endpoint domain: Adverse events/effects
Primary endpoint: Colorectal Cancer (CRC) Screening Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Respiratory rate (bpm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Temperature (°F or °C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight (lbs/kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subsequent unauthorized access violations
Endpoint domain: Adverse events/effects
Primary endpoint: Change in nasal conductance of airflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FAST+ pulmonary findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain on knee flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reproducibility of skin test to cyanobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fecal incontinence (Wexner score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on the faecal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on faecal microbiota activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in faecal water short chain fatty acids (SCFAs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Time Blood Glucose Values Less Than 70 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation of sputum cytological atypia with lung cancer incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correlation of changes in sputum cytology with lung cancer incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Range of motion in sagittal plane at the operated level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Audibility improvement (Delta of dB SPL thresholds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphological asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and microbiological cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Face recognition by the infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expressive language development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receptive language development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Solicited Adverse Events (AEs) Through 7 Days Post Each Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Unsolicited AEs Through 28 Days Post Each Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious AEs (SAEs) through end of study
Endpoint domain: Adverse events/effects
Primary endpoint: Iowa Family Interaction Rating Scales (IFIRS) scores
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Activation times of the RV and LV septum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary embolism detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urological outcomes
Primary endpoint: Grade of erosive oesophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Toxicity after neo-adjuvant treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Visual Acuity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evidence of vaccine-mediated protection against CHMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intra-tidal ventilation heterogeneity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC ∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vz/f
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GVHD free and relapse free survival at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: adverse metabolic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global Cognitive Score (Z-score)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of ATTRwt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Yale Food Addiction Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Three-Factor Eating Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement of Schirmer's Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased contact lens wear time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Surviving at 100 Days Post Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Proceeding to Transplant Following Induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in International Prostate Symptom Score (IPSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Major Device Related Serious Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of unprotected sexual occurrences
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: soft tissue volumetric changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity of mitochondria in skeletal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Acute and Subacute Toxicity (Grade 4 or 5 Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Chronic Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Impact of software on trial success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of software on trials to criterion (number of trials needed to achieve mastery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of software on total number of targets mastered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle, Nerve, or Vascular Damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total nicotine equivalents (TNE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stabilization of product use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NNK exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death, rehospitalisation for heart failure, reintervention, assist device implantation and stroke
Endpoint domain: Mortality/survival
Primary endpoint: Postural Trunk Asymmetry Index (POTSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients continuing TKI at 1st progression
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients discontinuing EGFR TKI at 1st progression
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients Who Died Within 2 Months of Entry Into the Study
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects Undergoing Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Outpatient Subject Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Progression of fibromuscular dysplasia lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Response Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency and Severity of Observed Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Partial/Complete Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of decline of visual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall survival (mOS)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients enrolling in HIV care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Occurrence of stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Occurrence of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in occurrence of lower limb ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Mean Difference in Apparent Diffusion Coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds Ratio (OR) Between Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average prevalence of MRSA colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in trough sitting diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Indeterminate results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest pain on the first five days after pleurodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest pain after 10 days of pleurodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest pain after 30 days of pleurodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upward malpositioning of ureteral stents
Endpoint domain: Adverse events/effects
Primary endpoint: systemic exposure and bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capsaicin-Induced Dermal Blood Flow (DBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plasma Calcitonin Gene-Related Peptide (CGRP) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of sedation with inhaled sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of Omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal Coagulation Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in VIGOR score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentration of budesonide in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wake after Persistent Sleep Onset (WAPSO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 100d Non-relapse mortality
Endpoint domain: Mortality/survival
Primary endpoint: 100d Graft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Any Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of calibration days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Investigator Global Assessment (IGA) Success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Coughing/Bucking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum NCC Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour area under the curve for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Study Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Levels of TNF in whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in breast cosmetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of days free from invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease Risk of COVID-19 Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in body composition parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of Change in Strength of Gluteus Medius Musculature (Hand Held Dynamometer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Degree of Change in Strength of Gluteus Medius Musculature (Surface Electromyography)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in oral lichen planus lesions severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: foreign body sensation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emotional Intelligence Competences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: absolute change in obstructive apnea hypopnea index (OAHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Spectroscopic features of skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cognitive Performance - Episodic Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Performance - Attention shifting
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Performance - Working Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Differentially regulated genes in airway epithelial and BAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patients Without Target Lesion Revascularization (TLR)
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of imaging variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: annual asthma exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: allele frequency for progression to bilateral advanced AMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge and attitudes about crying, shaking and abuse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Caregiver behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of Participants With a Vital Pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of Observed Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Immune-related Events of Clinical Interest (irECI)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of cART-related ECIs of Grade 2 or Higher AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in fatigue levels
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Loco-regional recurrence (LRR)
Endpoint domain: Mortality/survival
Primary endpoint: Survival, in terms of clinical or biological remission, at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Neurological toxicity
Endpoint domain: Adverse events/effects